Ken Griffin Vyne Therapeutics Inc. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$0.12 - $4.91 $3,918 - $160,350
-32,658 Reduced 37.71%
53,954 $8,000
Q3 2022

Nov 14, 2022
BUY
$0.24 - $4.27 $20,786 - $369,833
86,612 New
86,612 $19,000

Others Institutions Holding VYNE

# of Institutions
2
Shares Held
36.5K
Call Options Held
0
Put Options Held
0
View Full List

About VYNE Therapeutics Inc.

VYNE Quotes by TradingView
  • Ticker VYNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,005,600
  • Market Cap $179M
  • Description
  • VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, whi...
More about VYNE
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email